64 related articles for article (PubMed ID: 16125620)
1. Method for the determination of the levels of beta-amyloid peptide in the CSF sampled from freely moving rats.
El Mouedden M; Haseldonckx M; Mackie C; Meert T; Mercken M
J Pharmacol Toxicol Methods; 2005; 52(2):229-33. PubMed ID: 16125620
[TBL] [Abstract][Full Text] [Related]
2. Cisterna magna cannulated repeated CSF sampling rat model--effects of a gamma-secretase inhibitor on Aβ levels.
Shapiro JS; Stiteler M; Wu G; Price EA; Simon AJ; Sankaranarayanan S
J Neurosci Methods; 2012 Mar; 205(1):36-44. PubMed ID: 22226743
[TBL] [Abstract][Full Text] [Related]
3. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors.
El Mouedden M; Vandermeeren M; Meert T; Mercken M
Curr Pharm Des; 2006; 12(6):671-6. PubMed ID: 16472156
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein.
Irizarry MC; Deng A; Lleo A; Berezovska O; Von Arnim CA; Martin-Rehrmann M; Manelli A; LaDu MJ; Hyman BT; Rebeck GW
J Neurochem; 2004 Sep; 90(5):1132-43. PubMed ID: 15312168
[TBL] [Abstract][Full Text] [Related]
5. In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat.
Best JD; Jay MT; Otu F; Churcher I; Reilly M; Morentin-Gutierrez P; Pattison C; Harrison T; Shearman MS; Atack JR
J Pharmacol Exp Ther; 2006 May; 317(2):786-90. PubMed ID: 16443723
[TBL] [Abstract][Full Text] [Related]
6. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
Best JD; Jay MT; Otu F; Ma J; Nadin A; Ellis S; Lewis HD; Pattison C; Reilly M; Harrison T; Shearman MS; Williamson TL; Atack JR
J Pharmacol Exp Ther; 2005 May; 313(2):902-8. PubMed ID: 15743924
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two different methods for measurement of amyloid-β peptides in cerebrospinal fluid after BACE1 inhibition in a dog model.
Borghys H; Jacobs T; Van Broeck B; Dillen L; Dhuyvetter D; Gijsen H; Mercken M
J Alzheimers Dis; 2014; 38(1):39-48. PubMed ID: 23948925
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h.
Hawkins J; Harrison DC; Ahmed S; Davis RP; Chapman T; Marshall I; Smith B; Mead TL; Medhurst A; Giblin GM; Hall A; Gonzalez MI; Richardson J; Hussain I
Neurodegener Dis; 2011; 8(6):455-64. PubMed ID: 21389687
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.
Albright CF; Dockens RC; Meredith JE; Olson RE; Slemmon R; Lentz KA; Wang JS; Denton RR; Pilcher G; Rhyne PW; Raybon JJ; Barten DM; Burton C; Toyn JH; Sankaranarayanan S; Polson C; Guss V; White R; Simutis F; Sanderson T; Gillman KW; Starrett JE; Bronson J; Sverdlov O; Huang SP; Castaneda L; Feldman H; Coric V; Zaczek R; Macor JE; Houston J; Berman RM; Tong G
J Pharmacol Exp Ther; 2013 Mar; 344(3):686-95. PubMed ID: 23275065
[TBL] [Abstract][Full Text] [Related]
10. Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid.
Gabelle A; Roche S; Gény C; Bennys K; Labauge P; Tholance Y; Quadrio I; Tiers L; Gor B; Chaulet C; Vighetto A; Croisile B; Krolak-Salmon P; Touchon J; Perret-Liaudet A; Lehmann S
Brain Res; 2010 Oct; 1357():175-83. PubMed ID: 20713025
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
12. Systems Pharmacology Analysis of the Amyloid Cascade after β-Secretase Inhibition Enables the Identification of an Aβ42 Oligomer Pool.
van Maanen EM; van Steeg TJ; Michener MS; Savage MJ; Kennedy ME; Kleijn HJ; Stone JA; Danhof M
J Pharmacol Exp Ther; 2016 Apr; 357(1):205-16. PubMed ID: 26826190
[TBL] [Abstract][Full Text] [Related]
13. TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to γ-secretase modulation and amyloid-β₄₂ lowering by GSM-10h.
Hussain I; Harrison DC; Hawkins J; Chapman T; Marshall I; Facci L; Ahmed S; Brackenborough K; Skaper SD; Mead TL; Smith BB; Giblin GM; Hall A; Gonzalez MI; Richardson JC
Neurodegener Dis; 2011; 8(1-2):15-24. PubMed ID: 20689247
[TBL] [Abstract][Full Text] [Related]
14. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone and Aβ₂₅-₃₅ accelerate learning and memory impairments due to elevate amyloid precursor protein expression and neuronal apoptosis in 12-month male rats.
Li WZ; Li WP; Huang DK; Kan HW; Wang X; Wu WY; Yin YY; Yao YY
Behav Brain Res; 2012 Feb; 227(1):142-9. PubMed ID: 22061800
[TBL] [Abstract][Full Text] [Related]
17. Quantitative assessment of Aβ peptide in brain, cerebrospinal fluid and plasma following oral administration of γ-secretase inhibitor MRK-560 in rats.
Wu G; Wu Z; Na S; Hershey JC
Int J Neurosci; 2015; 125(8):616-24. PubMed ID: 25567290
[TBL] [Abstract][Full Text] [Related]
18. PEN-2 enhances gamma-cleavage after presenilin heterodimer formation.
Shiraishi H; Sai X; Wang HQ; Maeda Y; Kurono Y; Nishimura M; Yanagisawa K; Komano H
J Neurochem; 2004 Sep; 90(6):1402-13. PubMed ID: 15341524
[TBL] [Abstract][Full Text] [Related]
19. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
20. An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.
Lucey BP; Gonzales C; Das U; Li J; Siemers ER; Slemmon JR; Bateman RJ; Huang Y; Fox GB; Claassen JA; Slats D; Verbeek MM; Tong G; Soares H; Savage MJ; Kennedy M; Forman M; Sjögren M; Margolin R; Chen X; Farlow MR; Dean RA; Waring JF
Alzheimers Res Ther; 2015; 7(1):53. PubMed ID: 26225140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
